Fredun Pharmaceuticals Ltd — Important, 18-12-2025: Company Update

Fredun Pharmaceuticals has issued an update detailing its preferential allotment of equity shares and warrants, clarifying previous disclosures for transparency. The company plans to issue 6,44,360 equity shares and 5,51,600 convertible warrants, with a face value of ₹10 per share. Post-issue, fully diluted paid-up capital will be ₹5.92 Cr. The proceeds, totaling ₹153.25 Cr, will fund a strategic expansion into integrated health, wellness, and pharmaceuticals, covering Pet Care, Human Care, and Pharma Generics divisions. Funds are allocated for brand marketing, CAPEX, R&D, working capital, and reserves, with initial international expansion planned for several countries.